TGF-beta

A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease. Read More

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis. Read More

Members of the Vanderbilt University Medical Center (VUMC) community and others whose lives and careers have been influenced by legendary cancer investigator, educator and administrator Harold (Hal) Moses, M.D., have endowed the Linda and Harold L. Moses, M.D. Career Development Fund. Read More

Although cancers arising from different areas of the large intestine are heterogeneous, they appear to use similar important tumorigenic pathways. Read More

TGF-beta signaling in the kidney was thought to be a target for reducing renal fibrosis, but Vanderbilt researchers report that fibrosis still occurs in the absence of TGF-beta signaling. Read More

A protein that degrades the “matrix” between cells participates in the development of lung metastases from primary breast cancer in mouse models and may be a good target for breast cancer treatment. Read More

A new mouse model offers insight into the signaling pathways that control oral cancers – and a platform for testing anticancer therapeutics. Read More

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process. Read More

Blocking a serotonin receptor may provide a novel therapy for heart valve disease. Read More

Targeting immune system proteins may keep prostate cancer from spreading to bone. Read More

Cellular pathways altered by chronic exposure to cigarette smoke may reveal new biomarkers to assess smoking-induced lung cancer risk. Read More

New information about signaling pathways involved in colorectal cancer could aid in assessing prognosis and identifying new therapeutic targets for the disease. Read More

Drugs that target “epigenetic” changes may help treat or slow the progression of lung cancer. Read More